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Abstract Human immunodeficiency virus type 1 (HIV)
infection presently affects more that 40 million people
worldwide, and is associated with central nervous system
(CNS) disruption in at least 30% of infected individuals.
The use of highly active antiretroviral therapy has lessened
the incidence, but not the prevalence of mild impairment of
higher cognitive and cortical functions (HIV-associated
neurocognitive disorders) as well as substantially reduced
a more severe form dementia (HIV-associated dementia).
Furthermore, improving neurological outcomes will require
novel, adjunctive therapies that are targeted towards
mechanisms of HIV-induced neurodegeneration. Identify-
ing such molecular and pharmacological targets requires an
understanding of the events preceding irreversible neuronal
damage in the CNS, such as actions of neurotoxins (HIV
proteins and cellular factors), disruption of ion channel
properties, synaptic damage, and loss of adult neurogenesis.
By considering the specific mechanisms and consequences
of HIV neuropathogenesis, unified approaches for neuro-
protection will likely emerge using a tailored, combined,
and non-invasive approach.
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Introduction
Over 40 million people worldwide are infected by human
immunodeficiency virus-1 (HIV) (UNAIDS/WHO), and,
while HIV is most well known for its devastating effects on
the immune system and the resulting acquired immunode-
ficiency syndrome (AIDS), it can also cause several
neurological disorders, collectively known as HIV-
associated neurocognitive disorders (HAND). HAND syn-
dromes (minor cognitive motor disorder, HIV-associated
mild neurocognitive disorder, and asymptomatic neuro-
cognitive impairment) are characterized by cognitive,
motor, and behavioral abnormalities (Kaul et al. 2005)
and are classified according to patient performance in areas
of neurological and behavioral functioning and neuropsy-
chological testing (Sacktor et al. 2001; Sacktor 2002;
McArthur 2004;A n t i n o r ie ta l .2007). Prior to the
widespread use of highly active antiretroviral therapy
(HAART), 20–30% of individuals with advanced HIV
infection displayed symptoms of the most severe HAND
disorder, HIV-associated dementia (HAD; Gonzalez-
Scarano and Martin-Garcia 2005; Kaul et al. 2005). Since
the widespread use of HAART, the incidence of HAD has
dramatically decreased; however, as many as 40% of HIV-
positive patients continue to suffer from HAND (Sacktor et
al. 2001; Sacktor 2002; McArthur 2004; Antinori et al.
2007). Furthermore, although the incidence of HAD has
decreased, its prevalence is actually increasing, due in part
to the longer life expectancy for individuals with HIV and
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Martin-Garcia 2005). The persistently high prevalence of
milder forms of HAND (Sacktor et al. 2004) suggests a shift
in the relative distribution of HAND subtypes in the post-
HAART era. In patients presenting with even the milder
forms of HAND, quality of life is greatly affected, with these
individuals suffering from disruptions in ability to perform
activities of daily living, perhaps most importantly, that of
adherence to the HAART regiment (MacArthur 2004).
HAD manifests as a subcortical dementia characterized
by psychomotor slowing, changes in mood and anxiety
levels and deficits in memory, abstraction, information
processing, verbal fluency, decision-making, and attention
(Navia et al. 1986; Grant et al. 1987; Price et al. 1988;
Portegies et al. 1993). Surprisingly, deficits in olfaction are
common in HAD, and the severity, onset, and progression
of the disease can reliably be characterized using well-
established olfactory tests (Graham et al. 1995; Razani et al.
1996; Westervelt et al. 1997; Hornung et al. 1998; Mueller
et al. 2002; Zucco and Ingegneri 2004; Vance 2007). As
this collection of symptoms would suggest, the brain
regions most commonly damaged in HAD are the basal
ganglia, deep white matter, hippocampus, and cerebral
cortex (Gorry et al. 2003). Pathological features of HAD
include pervasive reactive astrocytosis, myelin pallor,
activated resident microglia, infiltration by circulating
monocytic cells, perivascular inflammation, microglial
nodules, multinucleated giant cells, dendritic simplification,
and cell death, both astrocytic and neuronal (Gorry et al.
2003; Kaul et al. 2005). Interestingly, rather than closely
correlating with viral load in the central nervous system
(CNS), clinical signs of HAD more closely associated with
increased numbers of microglia, evidence of excitotoxins,
and selective neuronal damage and loss (Kaul et al. 2005).
These findings suggest that, although HIV invasion into the
brain may be a necessary initial step in HAD progression,
other mechanisms more directly lead to the functional
losses associated with this disease.
HIV infection in the central nervous system
HIV primarily infects cells of the immune system, and
untreated infection ultimately results in AIDS and eventu-
ally death in the vast majority of cases. Approximately 2–
3 weeks after the primary infection, a patient with HIV
infection enters the acute stage of infection, which presents
most commonly as fever, skin rash, oral ulcers, and
lymphadenopathy (Pope and Haase 2003). HIV specifically
infects and kills CD4+ T cells, monocytes, and macro-
phages, and at this early stage of infection, the virus
establishes a reservoir within the lymphoid tissue and enters
into the CNS. In lymphoid tissue, productively infected,
activated CD4+ T cells produce and release billions of
virions daily, accounting for the systemic viral load (VL)
detected by patient plasma sampling. Within the CNS the
virus establishes its reservoir within the perivascular and
perhaps the parenchymal macrophage populations (Morris
et al. 1999). Virus detected through sampling cerebrospinal
fluid (CSF) likely reflects contributions from both the
systemic and CNS reservoirs, with the CNS reservoir
contributing more to CSF VL in advanced infection (Ellis
et al. 2000; Ritola et al. 2005).
Neuropathogenesis of HAND: overview
While neuronal cell damage and death are clearly associ-
ated with the development of HAD/HAND symptoms, HIV
rarely, if ever, infects neurons themselves (McArthur et al.
2003; Gonzalez-Scarano and Martin-Garcia 2005; Kaul et
al. 2005). Rather, productive HIV infection in the brain
occurs in cells of the macrophage lineage, including
monocyte-derived perivascular macrophages and microglia
(Gorry et al. 2003; Kaul et al. 2005). According to the most
widely accepted model, HIV invades the brain through a
“Trojan Horse” method (Liu et al. 2002), crossing the
blood–brain barrier (BBB) through infected monocytes that
later differentiate into macrophages (Albright et al. 2003).
This can occur within 1–2 weeks after virus enters into the
systemic circulation (Davis et al. 1992; Gray et al. 1993).
Subsequent infection and activation of neighboring cells
occurs via direct contact with infected cells (Gonzalez-
Scarano and Martin-Garcia 2005). Cells directly contacted
by infected ‘Trojan horse’ cells include perivascular macro-
phages, astrocytes, and microglia (Williams and Hickey
2002; Gonzalez-Scarano and Martin-Garcia 2005). Impor-
tantly, while astrocytes do appear susceptible to HIV
infection, they do not develop productive infection, and
thus, perivascular macrophages and microglia are the only
resident CNS cells capable of increasing HIV infection in
the brain (Gorry et al. 2003; Gonzalez-Scarano and Martin-
Garcia 2005).
Considering that HAND symptoms are closely associat-
ed with neuronal damage and loss, and the observation that
HIV is unable to infect neurons, mechanisms other than
direct infection must mediate the neuropathogenesis of HIV
infection. Currently, two major models account for neuro-
degeneration and development of neurological symptoms in
HAND: the direct model and the indirect model. Each of
these models requires the initial productive infection of
perivascular macrophages and microglia. The direct model
proposes that viral proteins released from infected
monocyte-derived cells cause neuronal death through direct
interaction of viral proteins with neurons (Gonzalez-
Scarano and Martin-Garcia 2005; Kaul et al. 2005). The
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is mediated by the inflammatory response mounted by
infected and uninfected non-neuronal cells against HIV
infection and against HIV proteins released by directly
infected cells (Gonzalez-Scarano and Martin-Garcia 2005;
Kaul et al. 2005). Clearly, these two models are not
mutually exclusive.
The indirect model of neurodegeneration in HAND
centers upon soluble factors released by non-neuronal cells
as part of an inflammatory response to viral particles. When
activated through direct HIV infection or through exposure
to viral particles, macrophages and microglia release
numerous soluble molecules, including the viral proteins,
gp120, Tat, and Vpr (only released from infected cells),
quinolinic and arachidonic acids, nitric oxide (NO), platelet
activating factor, superoxide anions, matrix metallopro-
teases, chemokines, growth factors, and proinflammatory
cytokines, including tumor-necrosis factor (TNF; Albright
et al. 2003; Gonzalez-Scarano and Martin-Garcia 2005).
While some of these molecules, such as growth factors (i.e.,
brain-derived neurotrophic factor) and some β-chemokines
(i.e. regulated upon activation-normal T-cell expressed and
secreted (RANTES)), are believed to play a neuroprotective
role, a number of the other non-viral factors have proven to
be neurotoxic (Kaul and Lipton 1999; Klein et al. 1999;
Gonzalez-Scarano and Martin-Garcia 2005; Kaul et al.
2005). Additionally, NO and TNF impair the neuroprotec-
tive functions of astrocytes, including maintenance of the
BBB and glutamate reuptake, while also increasing rates of
astrocytic apoptosis (Gorry et al. 2003; Gonzalez-Scarano
and Martin-Garcia 2005). The concomitant release of
excessive excitatory amino acids and other N-methyl-D-
aspartate glutamate receptor (NMDAR) agonists, and a
reduction in glutamate reuptake can create an excitotoxic
environment that results in excessive activation of
NMDAR. Consequently, intraneuronal Ca
2+ concentrations
reach toxic levels, which results in production of free
radicals (including reactive oxygen species (ROS) and NO)
and in neuronal death (Gonzalez-Scarano and Martin-
Garcia 2005; Kaul et al. 2005). Oxidative processes and
the resulting stresses are capable of inducing cell death,
even in the absence of viral infection, as suggested by the
role of oxidative stress in a number of other neurodegen-
erative diseases (Mariani et al. 2005).
Neuropathogenesis of HAND: mechanisms
of inflammation-induced neuronal insults
Both past and recent studies have provided a compelling
argument for a role for inflammation in triggering events
leading to neurodegeneration in HIV infection. Pulliam et
al. (1997) first demonstrated that individuals with HAD
express higher levels of circulating activated CD14+
monocytes that co-expressed CD69 than non-HAD indi-
viduals, and hypothesized that these activated monocytes
enter the brain and subsequently initiate neurotoxin
production. Ryan et al. (2001) subsequently confirmed an
association between plasma soluble CD14 (sCD14) and
cognitive dysfunction in HIV infection. More recently,
Ancuta et al. (2008) showed that elevated sCD14 and
lipopolysachharide (LPS) levels are associated with HAD.
These observations support an independent study which
demonstrated that elevated systemic LPS levels and
immune activation in chronic HIV infection resulting from
microbial translocation are associated with HIV-induced
depletion of gut-associated lymphoid tissue (Brenchley et
al. 2006). These studies clearly support the hypothesis that
systemic immune activation/inflammation triggered by
HIV-induced transmicrobial translocation and monocyte
activation increases the risk for development of HAND
through trafficking of activated monocytes into the CNS.
The association between the abundance of activated
macrophages/microglia in the CNS, neuronal damage, and
cognitive dysfunction suggests that neuroinflammation
resulting from systemic immune activation and/or inflam-
mation triggers the neurodegeneration observed in HAND
(Glass et al. 1995). Numerous in vitro and in vivo studies
link HIV-induced inflammation-associated neurodegenera-
tion with macrophage proinflammatory cytokine/chemo-
kine production, excitotoxic neuronal injury, and oxidative
stress (Kaul et al. 2001; Gonzalez-Scarano and Martin-
Garcia). We will discuss each below.
a) Chemokine/cytokine effects. In response to HIV inva-
sion of the CNS, microglia and macrophages within the
brain mount an immune response that includes the
release of both α- and β-chemokines. Since neurons
express chemokine receptors (Horuk et al. 1997; Lavi
et al. 1997; Rottman et al. 1997; Miller and Meucci
1999; Coughlan et al. 2000; Meucci et al. 2000), this
HIV-induced inflammatory response may play a critical
role in the effects of HIV infection on the CNS. Studies
have found elevated levels of the α-chemokines,
CXCL10/P-1o and CXCL12/SDF-1α, in the brains
and CSF of HAD patients (Rostasy et al. 2003; Cinque
et al. 2005). α-chemokines, which are expressed in
many types of CNS cells even under normal conditions,
bind CXCR chemokine receptors, thereby signaling a
Gi protein-dependent increase in intracellular calcium.
α-chemokines can have both neuroprotective and
neurotoxic effects (Kaul and Lipton 1999; Zheng et
al. 1999; Khan et al. 2008). Specifically, depending on
conditions, CXCL12 can act to either enhance synaptic
transmission or to activate caspase-3. When cleaved by
matrix metallic proteinases, CXCL12 changes its
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enhances the neurotoxic functions of this chemokine
(Kaul and Lipton 1999; Zheng et al. 1999; Zhang et al.
2003; Vergote et al. 2006). Similarly, CXCL10, which
acts through CXCR3 without prior proteolytic cleav-
age, induces increase in intracellular calcium and
activation of caspase-3 upon binding to its receptor
(Sui et al. 2004, 2006).
In contrast to α-chemokines, β-chemokines are only
expressed at relatively low levels in the brain under normal
conditions. However, several β-chemokines are found at
increased concentrations in the CNS following HIV
infection: CCL2, MIP-1α, MIP-1β, and RANTES/CCL5
(Kelder et al. 1998). β-chemokines act through CCR
receptors, and, as with α-chemokines, they are capable of
both neuroprotective and neurotoxic functions in the brain
(Schmidtmayerova et al. 1996). CCL5, MIP-1α, and MIP-
1β all provide protection against gp120-induced neurotox-
icity in vitro (Meucci et al. 1998; Kaul and Lipton 1999).
Contrarily, CCL2 is associated with an increased risk of
HAND, which may be due to the role of this chemokine in
the brain as a monocyte chemoattractant. Furthermore,
microglia activated by interferons and astrocytes activated
by IL-1β and TNF-α express CCL2, which could also
contribute to the positive correlation between CCL2 levels
and increased risk of HAND (Kelder et al. 1998; Sevigny et
al. 2004, 2007; Ragin et al. 2006). Thus, β-chemokines
may contribute to neuronal toxicity via existing pathways
that are overstimulated by higher than normal concentra-
tions of these factors.
In addition to α- and β-chemokines, elevated levels of
the unique chemokine, fractalkine/CX3CL1, have also been
observed in the CSF of HAND patients (Pereira et al.
2001). CX3CL1, a member of the CX3C family of
chemokines, binds to endothelial cells and mediates
monocyte attachment, potentially increasing monocyte
migration across the blood–brain barrier and into the
CNS, further increasing inflammation in the brains of
patients with HIV infection (Ancuta et al. 2003; Geissmann
et al. 2003; Maslin et al. 2005). However, as with α- and β-
chemokines, CX3CL1 appears to have both positive and
negative effects in the brain and, specifically, has been
shown to provide a degree of protection against neurotox-
icity (Mizuno et al. 2003; Deiva et al. 2004; Limatola et al.
2005). Thus, a delicate balance of neuroprotective and
neurotoxic roles of the major players in this response likely
determine the effect on neurons of an HIV-induced
inflammatory response in the CNS. However, it seems that
much of the protective function of chemokines is a
counteraction to the negative effects of inflammation, such
as toxicity induced by increased intracellular calcium, and
that it may, therefore, be beneficial to treat HIV patients
with drugs that protect the brain from HIV-induced
inflammation.
b) Excitotoxicity. Excitotoxicity is the process by which
excess levels of an excitatory neurotransmitter or other
agent evokes prolonged periods of neuronal membrane
depolarization, thereby increasing calcium (Ca
2+) lev-
els, and consequently activating proteases, endonu-
cleases, and other enzymes which damage cellular
components. The most common form of excitotoxicity
in the CNS is glutamate excitotoxicity, which is
mediated by the NMDAR, a voltage and ligand-gated
calcium ion channel that generates excitatory postsyn-
aptic currents through calcium influx into the neuron.
The subunit composition of NMDAR varies throughout
neuronal development, and, to some degree, within
different brain regions (Lynch and Guttmann 2001,
2002). Thus, different brain regions can respond
differently to excess glutamate and other NMDAR
agonists, possibly accounting for region specific dam-
age in diseases in which excitotoxicity plays a role,
such as HAND.
Glutamate, the major excitatory neurotransmitter in
the CNS, must be maintained at physiological levels
within the synapse to prevent sustained, toxic calcium
influx (Rothman 1984;H y r ce ta l .1997). In the HIV-
infected brain, activated and infected macrophages release
excitotoxic molecules that act upon the NMDAR, includ-
ing released glutamate, QUIN, and the neurotoxic amine,
N-Tox, and therefore, may evoke damaging periods of
NMDAR activation (Giulian et al. 1990; Jiang et al. 2001;
O'Donnell et al. 2006). Furthermore, activated macro-
phages release factors that act in a paracrine fashion to
stimulate reactive CNS cells, most importantly the
astrocytes and microglia. Astrocytes, in particular, play a
critical role in the regulation of extracellular glutamate
concentrations within the brain (Gegelashvili and Schousboe
1997;K a n a i1997; Vandenberg 1998), and when activated
this normal maintenance function is altered. Therefore,
altered glutamate release and uptake is thought to be a major
pathway of neurodegeneration in inflammatory brain dis-
eases such as HIV infection (Kaul et al. 2001). Notably,
Ferrarese et al. (2001) reported that glutamate is elevated in
the CSF of HIV-infected individuals, further supporting a
role for glutamate-mediated excitotoxicity in the pathogen-
esis of HAND.
Although inward NMDAR-dependent currents evoked
by glutamate derived from astrocytes and infected macro-
phages/microglia are the most commonly cited contributor
to excitotoxic death in neurons of patients with HAND,
other ionic currents may also play a role in excitotoxicity
and neuronal dysfunction. Outwardly rectifying currents
shape the action potential, interspike interval, and after
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excitability. Prolonged exposure to glutamate evokes
NMDAR-mediated excitotoxicity, but it is not fully
understood how outwardly rectifying channels are modu-
lated in response to such stimuli. Compensatory mecha-
nisms are likely initiated in order to attempt to restore and
maintain the resting membrane potential. These changes in
ion channel biophysics are ultimately damaging to the
neuron in the long-term because equilibrium likely favors a
more depolarized voltage, thus depleting energy stores and
maintaining continual activation of ion channels and
calcium-dependent enzymes.
Any changes in ion channel properties, as well as
membrane excitability, ultimately affect the manner in
which a neuron operates and processes incoming synaptic
signals. With respect to ion channels, there are several ways
that HIV-related molecules can alter biophysical properties.
Channel mean open probability, open duration, unitary
conductance, or channel inactivation and deactivation all
can be affected by various factors released by HIV-infected
and/or HIV-activated immune cells in the CNS. TNF-α
evokes an increase in A-type K
+ currents in cultured
embryonic rat cerebral cortex neurons (Houzen et al.
1997), and immune-activated macrophage-conditioned me-
dia also increases transient A-type (IA), as well as delayed
rectifier (IK)K
+ current in cultured rat hippocampal neurons
(Hu et al. 2009). Glutamate produces a Ca
2+-dependent
dephosphorylation of Kv2.1 channels, which disrupts
channel clusters and increases mean open channel proba-
bility and conductance (Murakoshi et al. 1997; Misonou et
al. 2004). Further support for Kv channelopathy in HAD is
observed in gene expression profiling studies demonstrating
a markedly decreased expression of two voltage-dependent
K
+ channels, which could likely cause substantially
decreased Kv currents (Gelman et al. 2004). Kv channels
can regulate back-propagating action potentials by influ-
encing the postsynaptic NMDAR voltage-dependent Mg
2+
blockade, thereby decreasing overall membrane excitability
(Paulsen and Sejnowski 2000; Johnston et al. 2003;
Birnbaum et al. 2004). Hence, modulation of Kv channels
by some of these compounds could significantly affect
NMDAR activation, membrane excitability, and action
potential propagation. Given the numerous mechanisms
by which HIV infection in the brain can induce excitotox-
icity, from increases in extracellular glutamate to alterations
of the channels that mediate the electrochemical function-
ing of neurons, therapeutics directed against this particular
etiology of HAND are promising candidates for treatment.
c) Oxidative stress. In addition to inflammation and
excitotxocity, much evidence supports a significant
role for oxidative stress in the pathogenesis of HAND.
In fact, oxidative stress is a well-characterized down-
stream effect of both inflammation and excitotoxicity.
Changes in cellular lipid metabolism that occur as a
result of oxidative stress, produce characteristic mole-
cules, such as ceramide, sphingomyelin, and hydrox-
ynoneal, all of which are found in individuals
displaying HAND (Kaul et al. 2005; Sacktor et al.
2004). Additionally, oxidized proteins were detected in
the CSF of patients with HAND, further supporting a
role for oxidative stress in the development of this
disease (Turchan et al. 2003). Treating rat cortical
neuroglial cultures with gp120 results in glial produc-
tion of ROS and neuronal death, both of which are
blocked when the cultures are pre-treated with an
antioxidant (Wakabayashi et al. 2003). HIV-proteins
may directly increase oxidative stress to neurons by
inducing mitochondrial dysfunction and through inter-
actions with membrane or cytosolic bound proteins.
This finding implicates oxidative stress as an important
mode of neuronal death in the indirect model of HAND
neurodegeneration. Additional studies have demon-
strated neuroprotective capabilities of antioxidants in
vitro (Turchan et al. 2003), and therapeutic properties
of antioxidants in vivo in HIV patients, showing both
inhibition of mental deterioration and improvement of
general health (Shor-Posner et al. 2002). These findings
demonstrate a significant pathogenic role for oxidative
stress in HAND, and suggest that the endogenous
cellular antioxidant response may serve as a potential
therapeutic target in this disease.
Neuropathogenesis of HAND: consequences of chronic
neuroinflammation
The pathways of neuronal damage described above are
often considered the "classical" or "central" pathophysiol-
ogies of HAD. However, new and often neglected studies
have highlighted other consequences of neuroinflammation
in HIV-infected and HAD individuals, that when observed
in the light of physiological mechanism, become increas-
ingly important in the study of disease progression.
a) Synaptic disruption. In addition to neuronal death,
HAND is associated with neuronal damage, particularly
synaptic disruption. The etiologies described in this
review, specifically inflammation and excitotoxicity,
provide mechanisms by which this HIV-associated
synaptic damage may occur. Activation of calcium-
dependent proteases that disrupt the postsynaptic
density (PSD) is a likely mechanism by which synapses
may be altered in the HIV-infected CNS. The smooth
ER, which extends into the dendritic spine, contains IP3
receptors that are tethered to mGluR and NMDARs by
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Homer, and PSD-95 (Tu et al. 1999; Sheng and Kim
2000, Sheng and Sala 2001; Sheng and Hoogenraad
2007). Secondary IP3-mediated calcium influxes are
thought to play a role in LTP, however, prolonged
synaptic depolarization and IP3-mediated signaling can
also activate calpain proteases that can cleave PSD-95
which releases it from NMDAR (Lu et al. 2000). This
could cause a large-scale decoupling of the postsynap-
tic complex from IP3 receptors. Interestingly, PSD-95
loss is also a hallmark sign of neurodegeneration
(Gardoni 2008; Gardoni et al. 2009); hence, uncoupling
or disruption of the PSD may be an important step in
synaptic dysfunction and damage. Thus, inhibition of
IP3-mediated calcium currents may prevent calpain or
other protease activation, as well as block kinase
enzymes from phosphorylating and modulating Kv
channels. A summary of synaptic/cellular neurotoxic
pathways and synaptic damage is presented in Figs. 1
and 2 to recapitulate the major findings discussed in this
section and to illustrate the complexity of the patholog-
ical mechanisms evoked by CNS HIV infection.
b) Impairment of neurogenesis. The dogma of a fixed and
static CNS has been replaced by an understanding of
the brain as a plastic, complex, and highly dynamic
environment where new neurons are continually gen-
erated in adult animals through the process of adult
neurogenesis (ANG). ANG is not confined to rodents,
as recent work has demonstrated the occurrence of
ANG in humans and other primates (Eriksson et al.
1998; Gage 2000; Pencea et al. 2001; Kam et al. 2009).
In fact, recent studies have demonstrated that disrup-
tion of ANG is significantly involved in HAND and
other neurodegenerative diseases (ND; Haughey et al.
2002; Donovan et al. 2006;K e l l e h e r - A n d e r s s o n2006;
Chen et al. 2008; Galvan and Bredesen 2007;Z h a n ge t
al. 2007; Rodriguez et al. 2008; Taupin 2009). Further-
more, substantial evidence demonstrates that ANG is
involved in learning and memory, olfaction, and
anxiety-related behaviors (Revest et al. 2009), all of
which are functions that are disrupted in HAD and ND.
The two regions of the brain that contain the highest
amount of newborn neurons are the hippocampus and the OB
(Altman and Das 1965;A l t m a n1969; Lois and Alvarez-
Buylla 1993; Lois and Alvarez-Buylla 1994; Eriksson et al.
1998;G a g e2000). Neural progenitor cells (NPCs) arise in
the subventricular zone (SVZ) or the dentate subgranular
zone (SGZ). SVZ NPCs migrate laterally and superiorly
eventually terminating in the subependymal zone of the OB
and SGZ NPCs migrate superiorly into the dentate gyrus of
the hippocampus. After reaching their target destination,
Fig. 1 Toxicity pathways in-
duced by HIV-associated soluble
factors. Inflammatory molecules
released from microglia/macro-
phages and astrocytes evoke
NMDAR activation, as well as
activation of metabotropic gluta-
mate receptors (mGluR), receptor
tyrosine kinases (RTK), voltage-
gated potassium channels (Kv),
other G-protein-coupled recep-
tors (GPCR), and potentially
major histocompatability com-
plex subtype 1 receptors (MHC
I). Excess calcium influx, as well
as release of intracellular calcium
via IP3 receptors, leads to acti-
vation of calpains and other
calcium-dependent proteases,
which are known to cleave post-
synaptic density proteins such as
PSD-95 leading to synaptic dys-
function and disassembly
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forming inhibitory interneurons (Xiong et al. 2008). NPCs
migrate from the SVZ to the olfactory bulb via the rostral
migratory stream, which is lined with glial cells which
provide trophic support to the migrating NPCs. As NPCs get
closer to their destination, they begin to differentiate, and
form immature neurons. Immature neurons then begin to
synaptically integrate with already existing mature neurons.
HIV infection induces several processes by which ANG
could be interrupted. HIV-induced alteration of general
astrocyte function, including the trophic support these cells
provide for both mature and immature neurons, may impair
the proliferation and migration of NPCs and immature
neurons along their migratory route (Fig. 3). Under this
hypothesis, the OB, which is the most distant structure
along the RMS, would be affected first in the earliest stages
of the disease, which in fact is the case in most ND where
olfaction is perturbed, such as HAND (Graham et al. 1995;
Razani et al. 1996; Westervelt et al. 1997; Hornung et al.
1998; Mueller et al. 2002; Zucco and Ingegneri 2004;
Vance 2007). Not surprisingly, cell cycle machinery play a
role in regulating the fate of NPC (Herrup and Yang 2007).
Interestingly, cell cycle proteins, such as the transcription
factor, E2F1, and its regulator, the retinoblastoma gene
product, exhibit increased levels and altered expression
patterns in Alzheimer’s Disease (AD), PD, and HAND
postmortem tissue (Jordan-Sciutto et al. 2002a, b;H o g l i n g e r
et al. 2007). Consistent with a role for these proteins in
altered neurogenesis (Lee et al. 1992), mice carrying a gene-
targeted deletion of E2F1 display substantially reduced ANG
in the OB and hippocampus (Cooper-Kuhn et al. 2002).
Furthermore, doublecortin (DCX), a microtubule protein
expressed in immature neurons (Takacs et al. 2007), has
several promoter sites that are regulated by cell cycle
proteins, including the E2F consensus site (Karl et al.
2005). Thus, altered E2F1 function and a consequent
disruption of DCX in HAND may cause an interruption in
ANG, thereby contributing to the pathogenesis of these HIV-
associated disorders. The CNS relies heavily on plasticity,
hence, the disruption of ANG and its molecular regulation
could yield devastating consequences for circuits and brain
regions assaulted by HIV-induced toxicity.
Another mechanism by which HIV could impair ANG is
the perturbation of metabolism and associated insulin signal-
ing pathways. Insulin in the brain enhances working memory,
promotes neuronal survival, and regulates reproduction via
Fig. 2 Diagram detailing the
numerous processes evoked by
HIV infection in the brain that
affect neuronal function and
survival. Excess glutamate from
the extracellular fluid and re-
leased from astrocytes causes
excitotoxic mechanisms, such as
dendritic beading, sustained
NMDAR activation, increased
calcium influx, and increased
intracellular release of calcium.
Ultimately, these processes lead
to disruption of the postsynaptic
density and loss of synapses.
Viral proteins such, as gp120
and TAT, activate chemokine
receptors, CXCR4 and CCR5,
and can increase voltage-gated
calcium (Cav) channels and po-
tassium channels (Kv), leading
to activation of cellular death
pathways that result in mito-
chondrial depolarization, cyto-
chrome p450 (Cp450) release,
and ultimately DNA fragmenta-
tion associated with apoptosis.
Viral proteins can also evoke
increased Na
+/H
+ exchange,
thereby increasing the pH inside
astrocytes which promotes in-
creased glutamate release and
decreased glutamate uptake,
thereby furthering excitotoxic
damage
300 J Neuroimmune Pharmacol (2010) 5:294–309the hypothalamic–pituitary axis (Brüning et al. 2000)T h i s
hormone acts as a neuromodulator by affecting synaptic
plasticity and neurotransmitter release (Plum et al. 2005).
Importantly, several lines of evidence suggest that insulin
and insulin-like growth factor (IGF) are very important in
ANG. Hippocampal neural progenitor cells express the
insulin receptor (IR) and IGF-1 receptors, and insulin and
IGF-1 are known to stimulate ANG in the dentate gyrus.
ANG, synaptic plasticity and learning potential are signifi-
cantly compromised in the rodent model of type 1 diabetes
(Stranahan et al. 2008; Zhang et al. 2008), suggesting that
both endocrine and brain insulin play a substantial role in the
generation of new neurons (Kamal et al. 2000). Lang et al.
(2009) also show that ANG is severely impaired in the adult
type-2 diabetic GK rats, demonstrating that aberrant insulin
signaling or insulin resistance can disrupt ANG. IGF-1 also has
received considerable attention in recent years as a potential
modulator of ANG (Aberg et al. 2000, 2003; Lichtenwalner et
al. 2001; Trejo et al. 2004; Anderson et al. 2002; Perez-Martin
et al. 2003a, b). In adults, peripheral IGF-1 mediates an
exercise-induced enhancement of neurogenesis in the hippo-
campus (Trejo et al. 2001) and also has a direct proliferative
effect on adult hippocampal progenitor cells in culture (Aberg
et al. 2003). Intracerebroventricular infusion of IGF-1also
eliminates the modest decrease in ANG that occurs in
advanced geriatric animals (Lichtenwalner et al. 2001).
HIVinfectionaltersinsulinsignaling,glucosehomeostasis,
lipid distribution, and metabolism in patients with or without
HAART therapy (Grinspoon and Bilezikian 1992; Sellmeyer
and Grunfeld 1996; Grinspoon et al. 1998;K o t l e re ta l .
1999). Mechanisms of metabolic disruption in HIV-infected
patients remain unclear, but it is hypothesized that peripheral
chemokine signaling is at least partially involved in the
alteration of insulin and glucose homeostasis (Hardy et al.
2001; Carper et al. 2008). In addition, patients on HAART
therapy experience more pronounced metabolic disturbance,
leading to aberrant lipid distribution (Safrin and Grunfeld
1999). HAART and some medications used to treat
behavioral perturbations in HAD are known to cause a
prolonged form of insulin resistance (Grinspoon and
Bilezikian 1992; Hardy et al. 2001;H u g h e se ta l .2005;
Carper et al. 2008). Some of these medications can bind the
insulin receptor kinase domain and inhibit downstream
phosphorylation of targets, or reduce voltage-gated K
+
channels and other anion currents (Neye et al. 2006), which
are known to affect glucose sensitivity and insulin response
signaling (Xu et al. 2004;D e s i r2005;L ie ta l .2006;
Tschritter et al. 2006). Thus, altered signaling from the IR
Fig. 3 Diagram detailing the
various checkpoints of adult
neurogenesis that can be affect-
ed by HIV infection in the brain.
Neural progenitor cells and their
supporting astrocytes can be
damaged by inflammation asso-
ciated with HIV infection. Mul-
tinucleated giant cells and
microglia, especially near the
rostral migratory stream, could
also contribute to toxicity and
damage to NPCs and immature
neurons. Differentiating NPCs,
as well as their integration into
existing synaptic circuits, can
also be affected
J Neuroimmune Pharmacol (2010) 5:294–309 301could potentially cause a form of insulin resistance, and may
be one of the factors by which HAND continues to progress
in patients on HAART.
Therapeutics for HAND; current trials
and considerations
Recent and past clinical therapeutic trials for the treatment
of HAND have focused on drugs as adjuncts to current
HAART, and although only modest success with adjunctive
therapies has been achieved the need for more effective
protection against HAND has clearly been recognized
(Clifford et al. 2009). In addition more effective utilization
of HAART drugs, based upon individual drug CNS penetra-
tion and efficacy represents an immediate approach, and more
effective delivery of HAART drugs through nanoparticle
delivery offers exciting possibilities for future consideration
(Dou et al. 2009). Some adjunctive therapies to HAART
studied thus far include NMDAR antagonists, calcium
channel blockers, antioxidants, and anti-inflammatory
drugs that either specifically or non-specifically target
suspected key pathways in HIV-induced neuronal injury.
Several recent, large-scale trials conducted through the
AIDS Clinical Trials Group (ACTG) focus on three of
these drugs: minocycline, memantine, and selegiline.
Minocycline: anti-inflammatory
Minocycline is a second-generation tetracycline antibiotic
derivative developed in the 1960s, and has become an
attractive drug candidate to treat HAND and other
neurodegenerative diseases. In addition to the antibiotic
properties of this molecule, it also potentially has protective
and anti-inflammatory effects in the CNS. Minocycline is
able to cross the blood–brain barrier at a substantial rate
(Colovic and Caccia 2003), thus allowing delivery at much
lower concentrations than other medications. Minocycline
has neuroprotective effects in quite a few models of
neurodegenerative diseases, as well as in traumatic and
ischemic brain injury (Chen et al. 2000; Du et al. 2001;
Sanchez Mejia et al. 2001; Arvin et al. 2002; Van Den
Bosch et al. 2002; Wu et al. 2002; Metz et al. 2004).
Minocycline has the advantages of being inexpensive to
produce, readily available in the pharmaceutical market,
and safe to administer over a long treatment time course.
The mechanisms by which minocycline could potentially
provide protection against HAND are numerous. Minocy-
cline suppresses JNK activation and lowers nitric oxide
levels in the brain in SIV models of infection (Follstaedt et
al. 2008), and, in parallel with this finding, minocycline
suppresses NO-induced activation of p38 and JNK in vitro.
Moreover, minocycline can inhibit ASK1 activation and
disrupts the cyclical inflammation/virus replication that is
often the precursor to the encephalitic state (Zink et al.
2005). Neuroprotective properties of minocycline are also
linked to suppressed activation of p38 mitogen-activated
protein kinase, a key physiopathology of SIV encephalitis
(Barber et al. 2004). In addition, minocycline can also
protect the brain by inhibiting the immune cell infiltration
and activation of microglia that lead to encephalitis (Tikka
and Koistinaho 2001; Tikka et al. 2001; Zink et al. 2005).
Finally, minocycline significantly inhibits HIV and SIV
replication in vitro (Zink et al. 2005), making this drug an
excellent candidate for limiting HIV replication within the
brain, which has remained a difficult anatomical compart-
ment for therapeutic interventions for HIV due to the lack
of BBB permeability of many such drugs. A multicenter
study of minocycline for the treatment of HAND
(ACTG5235) is currently underway (http://clinicaltrials.
gov/ct2/results?term=HIV+dementia).
Memantine: anti-excitotoxicity
Memantine is a voltage-dependent, open channel NMDAR
blocker that decreases prolonged conductance of calcium
via a simple uncompetitive bimolecular reaction with the
receptor that does not appear to interfere with physiological
function (Chen and Lipton 1997; Rammes et al. 2008).
Memantine is effective in gp120 transgenic mice and HIVE
SCID mice. Furthermore, it appears to have some efficacy
in clinical trials in patients with Alzheimer’s Disease,
another neurodegenerative disease associated with excito-
toxicity (Raber et al. 1996; Anderson et al. 2004; Lipton
and Chen 2003; Tariot et al. 2004), and is, in fact, currently
FDA-approved for AD treatment.
TheneuroprotectivepotentialforNMDARantagonistssuch
as memantine, in cases of HAND has recently been investi-
gated in a therapeutic multicenter trial of Namenda (mem-
antine; Schifitto et al. 2007b). However, no clinically
significant benefit in neuropsychological and behavioral
testing performance was observed during the 16-week
treatment phase of the trials, though there were potential
neuroprotective effects demonstrated by magnetic resonance
spectroscopy in the frontal white matter and parietal cortex in
treated individuals. Further trials of pharmaceuticals that
block excitotoxic pathways, in particular glutamate and QUIN
production, and trial designs of longer duration are clearly
needed and are likely to follow in the future (Bandaru et al.
2007;B r e we ta l .2007; Clifford 2008; Evans et al. 2007).
Selegiline: antioxidant
Selegiline is a monoamine oxidase type B inhibitor
(MAOIB) that has recently been used in clinical trials for
the treatment of HAD (Sacktor et al. 2000; Schifitto et al.
302 J Neuroimmune Pharmacol (2010) 5:294–3092007a, 2009). There is evidence that Selegiline has a low-
dose trophic effect on neurons, and also can reduce
oxygenated free radicals. Transdermal administration of
Selegiline results in less monoamine peripheral metabolites
than the oral route, suggesting that certain toxicities may be
avoided with higher transdermal doses of this pharmaceu-
tical (Schifitto et al. 2007a, 2009). However, the most
recent study with the transdermal application system did
not yield expected results (Schifitto et al. 2009). This system
demonstrated no effect on either magnetic resonance
spectroscopy metabolites or protein carbonyl concentration
from CSF, which can be a measure of oxidative stress. The
authors hypothesize that changes in oxidative stress may
occur before neural imaging performed in this study; hence,
selegiline may yet prove to be an effective treatment as
more advanced clinical analyses become available.
Therapeutics for HAND; future considerations
for adjunctive therapies
In addition to current treatment approaches (HAART drug
delivery, NMDAR antagonists, antioxidants, and anti-
inflammatory drugs), novel agents and routes of delivery
are also under consideration. Recent successes in the CNS
delivery of trophic factors (insulin, IGF-1, and neuro-
trophin) have provoked interest in these agents as neuro-
protectants against HIV. The development of intranasal
delivery (IND) of neurotrophin, insulin, and IGF-1 has
emerged as a potential therapeutic technique to reduce
damage associated with stroke and memory degeneration
associated with HAND, AD, or diabetes (Kern et al. 1999;
Thorne and Frey 2001; Benedict et al. 2004; Thorne et al.
2004, 2008; Ross et al. 2004; Reger et al. 2008a; Reger et
al. 2008b; Hanson and Frey 2007; Reagan 2007; Ross et al.
2008). IND allows rapid delivery from the nose to the CNS
via an extracellular route, which does not require selective
hormone binding or axonal transport mechanisms (Dhanda
et al. 2005; Hanson and Frey 2007). One of the most
interesting aspects of IND is that after molecule adminis-
tration, there is virtually no rise in blood concentration of
that particular molecule. Insulin, IGF-1, FGF-2, and HB-
EGF have all been tested intranasally and were not elevated
in the serum of the test subjects/animals nor were peripheral
glucose levels affected (Jin et al. 2003; Thorne et al. 2004;
Reger et al. 2006; Hanson and Frey 2007, 2008; Reger et
al. 2008a, b; Marks et al. 2009). Delivery time and
clearance rates are also quite remarkable for IND, where
some studies show anywhere from 6 to 20 min of peak
concentration (Thorne et al. 1995, 2004) and 4–9ho f
clearance from the CSF (Thorne et al. 2004; Hanson and
Frey 2007). Delivery systems for IND are fairly simple,
mimicking commercially available nasal spray mechanical
design, or for murine models, a standard P10-20 pipetteman
and associated sized plastic tip (Thorne et al. 2004;B e n e d i c t
et al. 2007; Hanson and Frey 2007; Francis et al. 2008;
Marks et al. 2009). There is also no associated damage to the
olfactory epithelium, olfactory bulb, or disruption of olfac-
tory receptor neuron axonal targeting (Marks et al. 2009).
Thus, for drug delivery to the CNS, IND appears to be a
non-invasive, fast, safe, and cost-effective solution with little,
if any, of the peripheral side effects that are often associated
with oral and site-injection medications.
IND of insulin and other molecules has been demon-
strated to mitigate many of the behavioral and patholog-
ical deficits associated with HAND and other ND.
Specifically, Marks et al. (2009) demonstrated that chronic
intranasal insulin delivery enhances odor discrimination
and short- and long-term memory, as well as reduces
anxiety. Reger et al. (2006, 2008a, b) also demonstrated
that acute intranasal insulin delivery enhances memory in
AD patients. IND also has rapid and continual effects
where subjects receiving acute and/or chronic IND insulin
have reported extended periods of enhanced mood,
reduced anger, and enhanced self-confidence in clinical
trials (Benedict et al. 2004). In a recent comprehensive
review of HAND pathophysiology, the authors state "Now
more than ever, patients are in need of therapy in
combination with ART in order to alleviate the potentially
greater neuropsychological decline over a longer lifespan"
(Ferris et al. 2008). Thus, a combined HAART and
intranasal therapy intended to address multiple etiologies
of HIV-induced damage in the CNS could be a promising
regimen for persons at high risk for HAND.
Conclusion
The therapeutic targets for HAND neuroprotection discussed
in this review, as well as others, clearly need further
consideration if effective treatment regimens for HAND are
to be identified and developed. We believe that effective
control of CNS viral replication through HAART is the
essential primary approach, but that it should be comple-
mented with adjunctive CNS-directed therapeutics. HIV-
induced inflammation and its consequences, expressed both
systemically and within the CNS, are attractive targets that
could be approached through multiple pharmacologic agents.
Minocycline is a promising candidate for treating the negative
effects of this inflammatory response. Excitotoxicity is
another mechanism of neural damage evoked by HIV and
HIV-related molecules in the brain. The open-channel
NMDARblocker,memantine,hasprovenbeneficialinanimal
models of HAND, but the recently published short-term
clinical trial results are disappointing, and it is thus unclear
how successful this agent will be in the long-term. The
J Neuroimmune Pharmacol (2010) 5:294–309 303possibilities for antioxidant therapies to reduce oxidative
stress are quite numerous. Selegiline is one of many
antioxidants, but it also yielded disappointing results in a
recent short-term clinical trial. It is clear that the possibilities
for future HAND treatments abound and that novel classes of
potential neuroprotectant agents as well as increased duration
of clinical trial testing and novel routes of administration
should be strongly considered in future trials.
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